Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Modo

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
BMC Neuroscience|July 18, 2009
Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT(1A) agonist in rat models of ischaemic strokeMaria Ashioti, John S Beech, Andrew S Lowe, et al.
Translational Psychiatry|January 17, 2013
Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathwaysV Mondelli, C Anacker, A C Vernon, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 1, 2015
Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant dosesMarie-Caroline Cotel, Ewelina M Lenartowicz, Sridhar Natesan, et al.
Psychological Medicine|August 13, 2016
Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume lossW R Crum, F Danckaers, T Huysmans, et al.
Neuroprotection|January 15, 2024
Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)Jie Liu, Heleen van Beusekom, Xian-Le Bu, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
BMC Neuroscience|July 18, 2009
Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT(1A) agonist in rat models of ischaemic strokeMaria Ashioti, John S Beech, Andrew S Lowe, et al.
Translational Psychiatry|January 17, 2013
Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathwaysV Mondelli, C Anacker, A C Vernon, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 1, 2015
Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant dosesMarie-Caroline Cotel, Ewelina M Lenartowicz, Sridhar Natesan, et al.
Psychological Medicine|August 13, 2016
Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume lossW R Crum, F Danckaers, T Huysmans, et al.
Neuroprotection|January 15, 2024
Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)Jie Liu, Heleen van Beusekom, Xian-Le Bu, et al.
Pageof 2